The FDA has granted Motif Neurotech approval to begin human trials of its Motif XCS System, a brain implant aimed at treatment‑resistant depression. The RESONATE study will follow patients for a year ...
Medical Device Network on MSN
Motif Neurotech secures FDA IDE to initiate depression implant study
Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
While we focused solely on its encryption and content filtering capabilities for this review, please note that the XCS 570 offers a host of other features to help control the flow of data in and out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results